本文来自 PingCAP 联合创始人兼 CTO 东旭的内部分享，有删减 大多数人以为战争是由拼搏组成的，其实不是，是由等待和煎熬组成的。—— 王兴 我们创业这一路上没有那么多惊心动魄，可能最重要的就是那么几个决定，以及，有些事情就不要决定。 那做海外市场，最重要的是什么？ 就是创始人心态的转变。 要看它对你来说是一个战略还是第二曲线的尝试，而战略的最好定义就是「不做就会死」。只有当你觉得 这件事不做会死的时候，才能把海外市场真的做好。 在尝试全球化的时候，我们踩了很多坑，回头复盘，核心原因就是那几年在国内太舒服了——客户收入不 错、经济环境不错、也拿了很多融资。 就是因为国内的业务很好，所以就没想过失败了怎么办，就每次去美国都当是出差，转两圈就回来了。 所以现在回头来看，当时犯的第一个错误就是没有把全球化当做一个「不做就会死」的事。 第二个错误，就是说我们要「出海」。 「全球化」和「出海」这两个词听起来差不多，但其中的区别真的大了去了。 在 2017 年的时候，我们说要做「出海」。 出海这件事情映射到 PingCAP 的组织上，就是中间划出了一个出海部门。 但我们执行了一两年，发现状态不太对。为什么？因为世界 ...

Group 1: Financial Performance - In 2024, the revenue from the system device business increased by 85%, but installation and debugging costs accounted for over 25% of the revenue [4] - The revenue from the life sciences sector reached 5.68 billion yuan, with a growth rate of 28% [14] - The revenue from the water treatment and ultrapure water business grew by 20%, with a total revenue of 6.88 billion yuan [7] Group 2: Operational Efficiency - The inventory turnover days extended to 180 days due to increased stock of system devices [4] - The company aims to reduce work-in-progress inventory by 25% through digital twin technology optimization [4] - The company achieved a 5-fold increase in inspection efficiency by replacing manual visual inspection with AI visual detection [3] Group 3: Market Expansion and Strategy - In 2024, overseas revenue accounted for 38% of total revenue, amounting to 6.55 billion yuan [10] - The company plans to enhance market development efficiency through the release of industry solution white papers covering six major fields [5] - The life sciences sector's revenue share increased to 29%, with a focus on new product development in peptide synthesis [5] Group 4: Research and Development - The R&D investment intensity reached 9.8%, but the patent implementation rate was below 45% [9] - The company holds 66 domestic and 13 foreign authorized patents, with 74 domestic and 103 foreign patents in the application stage [9] - The company is focusing on developing new types of polyethylene glycol carriers to increase drug loading capacity by 20% [5] Group 5: Supply Chain and Risk Management - The company reported no supply chain security challenges, with most raw materials already localized [12] - The accounts receivable turnover days extended to 125 days, with 65% of accounts receivable from system device projects [10] - The company is exploring credit insurance to cover 80% of accounts receivable to improve cash flow [10]

Definitive Healthcare (DH) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Matt Ruderman - Chief Legal Officer & Corporate SecretaryKevin Coop - Director & CEORick Booth - Chief Financial OfficerCasey Heller - SVP - FinanceJared Haase - Equity Research AssociateCraig Hettenbach - Executive DirectorDavid Grossman - Managing DirectorJenny Shen - Equity Research Associate Conference Call Participants George Hill - Managing Director & Equity Research Analyst Operator Welcome to Definitive He ...